Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03628677
Title A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Arcus Biosciences, Inc.

head and neck squamous cell carcinoma

renal cell carcinoma

breast cancer

Merkel cell carcinoma

urinary bladder cancer

colorectal cancer

ovarian cancer

endometrial cancer

lung non-small cell carcinoma


gastroesophageal cancer



AB154 + Zimberelimab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.